Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review

被引：1

作者：

Schmidt, Stefanie ^{[1
]}

Kunath, Frank ^{[1
,2
]}

Coles, Bernadette ^{[3
]}

Draeger, Desiree Louise ^{[1
,4
]}

Krabbe, Laura-Maria ^{[1
,5
]}

Dersch, Rick ^{[6
]}

Kilian, Samuel ^{[7
]}

Jensen, Katrin ^{[7
]}

Dahm, Philipp ^{[8
,9
]}

Meerpohl, Joerg J. ^{[10
,11
]}

机构：

[1] UroEvidence Deutsch Gesell Urol, Berlin, Germany

[2] Univ Hosp Erlangen, Dept Urol, Erlangen, Germany

[3] Cardiff Univ Lib Serv, Velindre NHS Trust, Cardiff, Wales

[4] Univ Rostock, Dept Urol, Rostock, Germany

[5] Univ Muenster Med Ctr, Dept Urol, Munster, Germany

[6] Univ Freiburg, Med Ctr, Fac Med, Clin Neurol & Neurophysiol, Freiburg, Germany

[7] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany

[8] Minneapolis VA Hlth Care Syst, Urol Sect, Minneapolis, MN USA

[9] Univ Minnesota, Dept Urol, Minneapolis, MN USA

[10] Univ Freiburg, Med Ctr, Fac Med, Inst Evidence Med, Freiburg, Germany

[11] Cochrane Germany Fdn, Cochrane Germany, Freiburg, Germany

来源：

INVESTIGATIVE AND CLINICAL UROLOGY | 2020年 / 61卷 / 04期

关键词：

Administration; intravesical; BCG vaccine; Mitomycin; Systematic review; Urinary bladder neoplasms; THERAPY; TRIAL; MULTICENTER; RECURRENCE;

D O I：

10.4111/icu.2020.61.4.349

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：349 / 353

页数：5

共 17 条

[1]

[Anonymous], 2014, Cochrane handbook for systematic reviews of interventions version 5.1.0

[2]

[Anonymous], 2014, The Nordic Cochrane Centre: Review Manager (RevMan) [Computer program]

[3]

[Anonymous], Cochrane Database of Systematic Reviews, DOI DOI 10.1002/14651858.CD003231

[4] Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity [J].

Böhle, A ;

Jocham, D ;

Bock, PR .

JOURNAL OF UROLOGY, 2003, 169 (01) :90-95

[5]

ClinicalTrials.gov, 2009, MIT C VERS BAC CALM

[6] Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study [J].

Di Stasi, SM ;

Giannantoni, A ;

Stephen, RL ;

Capelli, G ;

Navarra, P ;

Massoud, R ;

Vespasiani, G .

JOURNAL OF UROLOGY, 2003, 170 (03) :777-782

[7] Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma [J].

Friedrich, Martin G. ;

Pichlmeier, Uwe ;

Schwaibold, Hartwig ;

Conrad, Stefan ;

Huland, Hartwig .

EUROPEAN UROLOGY, 2007, 52 (04) :1123-1130

[8] Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer [J].

Gardmark, Truls ;

Jahnson, Staffan ;

Wahlquist, Rolf ;

Wijkstrom, Hans ;

Malmstrom, Per-Uno .

BJU INTERNATIONAL, 2007, 99 (04) :817-820

[9] Long-term Efficacy of Maintenance Bacillus Calmette-Guerin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up [J].

Jarvinen, Riikka ;

Kaasinen, Eero ;

Sankila, Anna ;

Rintala, Erkki .

EUROPEAN UROLOGY, 2009, 56 (02) :260-265

[10] A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin [J].

Krege, S ;

Giani, G ;

Meyer, R ;

Otto, T ;

Rubben, H ;

Noll, F ;

Jakse, G ;

Melchior, HJ ;

Weissbach, L ;

Terhorst, B ;

Lenz, P ;

Faul, P ;

Sommerkamp, H ;

Kopper, B ;

Hautmann, R ;

Knebel, L ;

Eisenberger, F ;

Schaffner, W .

JOURNAL OF UROLOGY, 1996, 156 (03) :962-966

← 1 2 →